Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.

Authors

Ezra E.W. Cohen

Moores Cancer Center, University of California San Diego, La Jolla, CA

Ezra E.W. Cohen , Christophe Le Tourneau , Richard Schaub , Matthias Bartenstein , Lulu Cheng , Lisa F. Licitra

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530).

First Author: Dan Paul Zandberg

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.

First Author: Dean F. Bajorin

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

First Author: Jared Cohen

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

First Author: Nourhan El Ahmar